Revance Therapeutics

Revance Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development, manufacturing, and commercialization of novel botulinum toxin products for multiple aesthetic and therapeutic applications. The firm focuses on production of daxibotulinumtoxinA, a botulinum toxin, for aesthetic and therapeutic indications including facial wrinkles and muscle movement disorders. The company was founded by Jacob M. Waugh and L. Daniel Browne on August 10, 1999 and is headquartered in Nashville, TN.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revance Therapeutics excels in Q4 with DAXXIFY approval driving growth

Revance Therapeutics demonstrated strong financial performance and strategic focus in Q4 2022, driven by DAXXIFY sales and revenue growth.
The company's strengths lie in DAXXIFY approval, positive market feedback, and partnerships positioning them well for future growth.
Challenges include competitive dynamics, pricing strategies, and managing increased OpEx, while opportunities exist in market expansion and new product programs.
Overall, Revance is optimistic about their market position and future prospects, emphasizing customer relationships and strategic investments.

Revance Therapeutics posts stellar Q1 results, eyes market expansion

Revance Therapeutics delivered strong Q1 results, driven by robust RHA Collection and DAXXIFY sales, positioning the company for future growth.
While facing challenges in undisclosed market data and paused clinical trials, Revance's strategic focus on market entry and product adoption presents opportunities for expansion.
With a solid cash position, upcoming milestones, and market potential, Revance is poised for continued success in the neuromodulator and therapeutics segments.

Revance Therapeutics reports record revenue growth and strategic expansion

Revance Therapeutics had a robust Q2 2023, marked by strong revenue growth, expanded sales force, and successful marketing efforts.
While facing challenges in market reception and adoption rates for DAXXIFY, the company remains optimistic about driving growth and leveraging opportunities.
With a focus on sales force expansion, product education, and strategic initiatives, Revance is poised for continued commercial progress and success.

Revance Therapeutics reports strong Q3 growth driven by DAXXIFY

Revance Therapeutics is strategically focusing on DAXXIFY launch success, aesthetics growth, and therapeutics opportunities. Despite challenges in account responses and revenue guidance uncertainties, the company remains optimistic about expanding DAXXIFY adoption and maintaining a strong financial position.

Revance Therapeutics reports record revenue, eyes growth in 2024

Revance Therapeutics had a strong performance in 2023, focusing on growth and cost controls for future success.
The company's strategic initiatives and product offerings position it well for continued growth and market expansion.
Challenges in managing expenses and achieving profitability are being addressed with targeted strategies.
Optimism surrounds the potential of DAXXIFY and the company's ability to capitalize on market opportunities.

Revance Therapeutics (RVNC) reports strong Q1 performance and strategic market entry

Revance Therapeutics (RVNC) demonstrated strong performance in Q1 2024, driven by growth in DAXXIFY and RHA filler market share, with a strategic entry into the therapeutic neurotoxin market.
The company's focus on innovation, efficiency, and market expansion presents opportunities for revenue growth and competitive positioning, despite challenges in differentiation and market dynamics.
Efforts to drive product adoption, enhance customer engagement, and optimize operational efficiency underscore Revance's commitment to sustainable financial health and long-term success.
Overall, Revance's Q1 performance reflects positive momentum and strategic initiatives aimed at capitalizing on market opportunities and strengthening its competitive position.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Revance Therapeutics, Inc. (RVNC) CEO Mark Foley on Q3 2020 Results - Earnings Call Transcript

Shares of Revance Therapeutics (NASDAQ:RVNC) decreased 8.62% in after-market trading after the company reported Q3 results. Quarterly Results Earnings per share were down 39.58% year over year to ($1.34), which missed the estimate of ($1.03).

Recap: Revance Therapeutics Q3 Earnings

Revance (RVNC) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Is a Surprise Coming for Revance (RVNC) This Earnings Season?

Revance Therapeutics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating.
The post Stocks Showing Market Leadership: Revance Therapeutics Earns 93 RS Rating appeared first on Investor's Business Daily.

Stocks Showing Market Leadership: Revance Therapeutics Earns 93 RS Rating

Revance Therapeutics, Inc. (RVNC) CEO Mark Foley on Q2 2020 Results - Earnings Call Transcript

Revance Therapeutics (RVNC) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

Revance Therapeutics (RVNC) Surges: Stock Moves 5.5% Higher

Revance Therapeutics, Inc. (RVNC) CEO Mark Foley on Q1 2020 Results - Earnings Call Transcript

As of late, it has definitely been a great time to be an investor in Revance Therapeutics.

Revance's Shares March Higher, Can It Continue?

Revance (RVNC) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

How Revance (RVNC) Stock Stands Out in a Strong Industry

Investors need to pay close attention to Revance Therapeutics (RVNC) stock based on the movements in the options market lately.

Implied Volatility Surging for Revance Therapeutics (RVNC) Stock Options

Revance Therapeutics, Inc. (RVNC) CEO Mark Foley on Q4 2019 Results - Earnings Call Transcript

The company's frown line treatment moved closer to commercialization today.

The FDA Accepted Revance Therapeutics' Application for Approval Of Its Botox Competitor

Will Revance Therapeutics Continue to Surge Higher?

Revance Therapeutics: A Robust Pick For 2020

A new deal accelerates the company's shift to a commercial-stage biotech.

Why Revance Therapeutics Stock Is Jumping 13.1% Today

Revance Therapeutics: The Real Threat To Abbvie's Dividend

Dynatrace Inc

Immunomedics

Several companies raised capital on Wednesday.

Why Dynatrace, Revance Therapeutics, and Immunomedics Slumped Today

The pricing of a secondary offering is to blame.

Here's Why Revance Therapeutics Stock Is Falling Today

Revance Therapeutics, Inc. (RVNC) CEO Mark Foley on Q3 2019 Results - Earnings Call Transcript

Earlier this month, Revance Therapeutics Inc (NASDAQ: RVNC) named Mark Foley as its new CEO.

Wells Fargo Turns Bullish On Revance Therapeutics After Meeting With Management

Hilton Worldwide Holdings

21Vianet Group

Possible merger and acquisition activity lifted one of these stocks.

Why Hilton Grand Vacations, 21Vianet Group, and Revance Therapeutics Jumped Today

Biotech Revance Therapeutics Inc. RVNC, +4.46% said Monday it has named Mark J. Foley as chief executive, replacing Dan Browne who has stepped down due to a misjudgment in handling an employee matter.

Revance CEO Dan Browne steps down due to 'misjudgment in handling employee matter'

Revance's DAXI seems to have a longer duration of effect than botox and its current competitors.

Revance: Brace For Competition In The Botox Market

Aerie Pharmaceuticals

Amazon

Salesforce

Concho Resources

Dropbox

Diamondback Energy

Nutanix

Boingo Wireless

Yext

These 10 monster growth stocks to buy all offer exciting opportunities. There's the important information for investors to keep in mind.

10 Monster Growth Stocks to Buy for 2019 and Beyond

Revance Therapeutics, Inc. (RVNC) CEO Daniel Browne on Q2 2019 Results - Earnings Call Transcript

News for Revance Therapeutics Stock (RVNC)